PL411390A1 - Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej - Google Patents

Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej

Info

Publication number
PL411390A1
PL411390A1 PL411390A PL41139015A PL411390A1 PL 411390 A1 PL411390 A1 PL 411390A1 PL 411390 A PL411390 A PL 411390A PL 41139015 A PL41139015 A PL 41139015A PL 411390 A1 PL411390 A1 PL 411390A1
Authority
PL
Poland
Prior art keywords
diabetes
type
level
wnt4
wnt3a
Prior art date
Application number
PL411390A
Other languages
English (en)
Inventor
Agnieszka Dobrzyń
Kamil Koziński
Original Assignee
Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk filed Critical Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk
Priority to PL411390A priority Critical patent/PL411390A1/pl
Priority to PCT/IB2016/051087 priority patent/WO2016135702A1/en
Priority to ES16714534T priority patent/ES2731294T3/es
Priority to US15/553,575 priority patent/US10222384B2/en
Priority to PL16714534T priority patent/PL3262420T3/pl
Priority to EP16714534.1A priority patent/EP3262420B1/en
Publication of PL411390A1 publication Critical patent/PL411390A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Sposób wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu drugiego, charakteryzuje się tym, że obejmuje ocenę poziomu białka wybranego spośród Wnt4 i Wnt3a w próbce biologicznej pochodzącej od pacjenta, zwłaszcza w osoczu, przy czym odbiegający od normy poziom tego białka wskazuje na występowanie stanu przedcukrzycowego lub cukrzycy typu drugiego, przy czym korzystnie uznaje się, że: o stanie przedcukrzycowym świadczy obniżony poziom Wnt4 lub podwyższony poziom Wnt3a, lub występowanie tych zaburzeń jednocześnie, o cukrzycy, zwłaszcza typu drugiego, świadczy podwyższony poziom Wnt4 i obniżony poziom Wnt3a. Przedmiotem zgłoszenia jest również zastosowanie poziomu białka wybranego spośród Wnt4 i Wnt3a, zwłaszcza w osoczu, do identyfikowania stanu przedcukrzycowego lub cukrzycy.
PL411390A 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej PL411390A1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL411390A PL411390A1 (pl) 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej
PCT/IB2016/051087 WO2016135702A1 (en) 2015-02-26 2016-02-26 A method for the early diagnosis of a pre-diabetic state and type 2
ES16714534T ES2731294T3 (es) 2015-02-26 2016-02-26 Método para el diagnóstico precoz de un estado prediabético y de diabetes tipo 2
US15/553,575 US10222384B2 (en) 2015-02-26 2016-02-26 Method for the early diagnosis of a pre-diabetic state and type 2 diabetes
PL16714534T PL3262420T3 (pl) 2015-02-26 2016-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2
EP16714534.1A EP3262420B1 (en) 2015-02-26 2016-02-26 A method for the early diagnosis of a pre-diabetic state and type 2 diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411390A PL411390A1 (pl) 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej

Publications (1)

Publication Number Publication Date
PL411390A1 true PL411390A1 (pl) 2016-08-29

Family

ID=55661489

Family Applications (2)

Application Number Title Priority Date Filing Date
PL411390A PL411390A1 (pl) 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej
PL16714534T PL3262420T3 (pl) 2015-02-26 2016-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16714534T PL3262420T3 (pl) 2015-02-26 2016-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2

Country Status (5)

Country Link
US (1) US10222384B2 (pl)
EP (1) EP3262420B1 (pl)
ES (1) ES2731294T3 (pl)
PL (2) PL411390A1 (pl)
WO (1) WO2016135702A1 (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
US20100055784A1 (en) 2007-03-02 2010-03-04 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
JP5246870B2 (ja) 2009-03-25 2013-07-24 独立行政法人産業技術総合研究所 インシュリン産生増強剤
WO2012109538A2 (en) 2011-02-10 2012-08-16 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof

Also Published As

Publication number Publication date
ES2731294T3 (es) 2019-11-14
PL3262420T3 (pl) 2019-11-29
EP3262420B1 (en) 2019-03-20
EP3262420A1 (en) 2018-01-03
US10222384B2 (en) 2019-03-05
WO2016135702A1 (en) 2016-09-01
US20180017574A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112014007214A2 (pt) predição de evento de risco cardiovascular e utilização do mesmo
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX364886B (es) Lente oftálmica con sistema microfluídico.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
WO2015193325A3 (en) Ceramides and their use in diagnosing cvd
IN2014DE01077A (pl)
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112013019563A2 (pt) métodos para prognóstico de ferida, para tratamento de ferida, para prognosticar se um paciente pode ser responsivo ao tratamento de uma ferida que exsuda um fluido de ferida, e para tratar uma ferida que exsuda um fluido de ferida, dispositivo para medir simultaneamente ou sequencialmente os níveis de hne e de pelo menos uma mmp em uma amostra de fluido de ferida, aparelho para diagnóstico, e, estojo.
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
NZ729773A (en) Biomarkers for disease progression in melanoma
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
MX2017009752A (es) Adn huesped como biomarcador de la enfermedad de crohn.
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
PL411390A1 (pl) Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej
WO2020115270A3 (en) Biomarker for detecting zearalenone effect
AU2018357933B2 (en) Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina